Stocks
Orexigen Therapeutics, Inc.OREX
YHDHealthcareBiotechnology$0.22-9.87%
Price as of · delayed, not real-time
Focused on developing treatments for obesity, this biopharmaceutical company gained attention for its weight-loss drug Contrave before facing regulatory and commercial challenges. Investors followed its volatile trajectory due to the high-stakes obesity drug market and eventual acquisition by Nalpropion Pharmaceuticals.
Market Cap: $052W Range: $0.17-$3.81
Congressional Interest in Orexigen Therapeutics, Inc. (OREX)
4 members of Congress have disclosed 4 trades in Orexigen Therapeutics, Inc. (OREX), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 2 sales. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
4
Unique Politicians
4
Buys
2
Sells
2
Who in Congress Is Trading OREX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2018-01-10 | KENNY MARCHANT | buy | $1K-$15K |
| 2018-01-05 | ALAN S. LOWENTHAL | sell | $11-$99 |
| 2016-03-08 | MICHAEL T. MCCAUL | sell | $15K-$50K |
| 2011-03-10 | JAMES B. RENACCI | buy | $1K-$15K |